We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-1.04%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$165M
AUM Growth
-$4.08M
Cap. Flow
+$2.01M
Cap. Flow %
1.22%
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54

Top Sells

Rank Stock Value
1
NFLX icon
Netflix
NFLX
+$1.05M
2
VMC icon
Vulcan Materials
VMC
+$1.01M
3
CSGP icon
CoStar Group
CSGP
+$998K
4
LLY icon
Eli Lilly
LLY
+$967K
5
IR icon
Ingersoll Rand
IR
+$913K

Sector Composition

Rank Sector Weight
1 Healthcare 18.63%
2 Financials 17.26%
3 Technology 14.89%
4 Energy 9.42%
5 Consumer Discretionary 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CCI icon
301
Crown Castle
CCI
$33.4B
$167K 0.1%
1,811
+60
+3% +$6.22K
GTY
302
Getty Realty Corp
GTY
$2.18B
$166K 0.1%
5,995
-408
-6% -$12.7K
BTG icon
303
B2Gold
BTG
$4.97B
$165K 0.1%
57,063
-753
-1% -$2.45K
BKH icon
304
Black Hills Corp
BKH
$5.63B
$164K 0.1%
3,251
-421
-11% -$23.9K
ES icon
305
Eversource Energy
ES
$28.2B
$163K 0.1%
2,807
-152
-5% -$10.1K
HR icon
306
Healthcare Realty
HR
$7.55B
$163K 0.1%
10,642
-1,323
-11% -$23.5K
GPCR icon
307
Structure Therapeutics
GPCR
$3.39B
$161K 0.1%
3,194
-319
-9% -$10.3K
TVTX icon
308
Travere Therapeutics
TVTX
$5.11B
$161K 0.1%
17,981
-2,328
-11% -$32.8K
PTCT icon
309
PTC Therapeutics
PTCT
$6.18B
$159K 0.1%
7,075
-914
-11% -$34K
LUMN icon
310
Lumen
LUMN
$6.33B
$152K 0.09%
107,340
+19,559
+22% +$33.1K
GFI icon
311
Gold Fields
GFI
$28.7B
$151K 0.09%
13,926
-3,547
-20% -$46.7K
DRD
312
DRDGold
DRD
$1.75B
$151K 0.09%
18,168
-5,582
-24% -$56.3K
CRNX icon
313
Crinetics Pharmaceuticals
CRNX
$8.88B
$144K 0.09%
4,849
-484
-9% -$9.97K
DKL icon
314
Delek Logistics
DKL
$3.1B
$144K 0.09%
3,435
-963
-22% -$42.6K
ENTA icon
315
Enanta Pharmaceuticals
ENTA
$365M
$143K 0.09%
12,784
-1,654
-11% -$26.6K
AU icon
316
AngloGold Ashanti
AU
$39B
$138K 0.08%
8,763
-1,213
-12% -$22.9K
BAK icon
317
Braskem
BAK
$944M
$136K 0.08%
16,562
-17,909
-52% -$173K
LXRX icon
318
Lexicon Pharmaceuticals
LXRX
$1.03B
$133K 0.08%
121,711
-15,739
-11% -$27.6K
APLS
319
DELISTED
Apellis Pharmaceuticals
APLS
$126K 0.08%
3,301
-429
-12% -$18.8K
MPT
320
Medical Properties Trust
MPT
$2.87B
$123K 0.07%
22,566
-7,257
-24% -$58.1K
EQRX
321
DELISTED
EQRx, Inc. Common Stock
EQRX
$121K 0.07%
54,639
-5,437
-9% -$11.6K
MRTX
322
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$117K 0.07%
2,684
-268
-9% -$9.57K
DVAX
323
DELISTED
Dynavax Technologies
DVAX
$116K 0.07%
7,831
-785
-9% -$11K
PGEN icon
324
Precigen
PGEN
$1.95B
$113K 0.07%
79,754
-7,938
-9% -$11.3K
TSVT
325
DELISTED
2seventy bio
TSVT
$111K 0.07%
28,308
-3,657
-11% -$24K

Similar funds

Virtus ETF Advisers's Q3 2023 Portfolio in Review

As of Q3 2023, Virtus ETF Advisers held 488 positions worth $165M, down 2.4% from $169M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.

Virtus ETF Advisers's Q3 2023 filing shows 53 new, 73 increased, 307 reduced and 54 closed positions. Its largest new stake was Alphabet (Google) Class A: 6,222 shares worth $814K. The largest sale was Netflix, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 28% a quarter earlier, followed by Financials and Technology.

  • Virtus ETF Advisers's largest Q3 2023 buy was Alphabet (Google) Class A: 6,222 shares worth $814K.
  • Virtus ETF Advisers added most to Coterra Energy in Q3 2023, an estimated $732K increase.
  • Virtus ETF Advisers's biggest Q3 2023 reduction was Incyte, cutting an estimated $701K.
  • Virtus ETF Advisers fully exited Netflix in Q3 2023, selling an estimated $1.05M.
  • Virtus ETF Advisers's ten largest holdings make up 6.1% of its $165M portfolio in Q3 2023.
  • Virtus ETF Advisers opened 53 new positions and closed 54 in Q3 2023.
  • Virtus ETF Advisers's portfolio value fell 2.4% quarter-over-quarter to $165M.

Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.